Form 8-K - Current report:
SEC Accession No. 0001104659-24-019884
Filing Date
2024-02-13
Accepted
2024-02-13 16:10:54
Documents
16
Period of Report
2024-02-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm245849d1_8k.htm   iXBRL 8-K 26620
2 EXHIBIT 99.1 tm245849d1_ex99-1.htm EX-99.1 63342
6 GRAPHIC tm245849d1_ex99-1img001.jpg GRAPHIC 5088
  Complete submission text file 0001104659-24-019884.txt   279164

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rzlt-20240213.xsd EX-101.SCH 3024
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rzlt-20240213_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rzlt-20240213_pre.xml EX-101.PRE 22365
17 EXTRACTED XBRL INSTANCE DOCUMENT tm245849d1_8k_htm.xml XML 3610
Mailing Address 275 SHORELINE DRIVE, SUITE 500 REDWOOD CITY CA 94065
Business Address 275 SHORELINE DRIVE, SUITE 500 REDWOOD CITY CA 94065 650-206-4507
Rezolute, Inc. (Filer) CIK: 0001509261 (see all company filings)

EIN.: 273440894 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-39683 | Film No.: 24625953
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)